What it is
CJC-1295 (no DAC) is a synthetic analog of growth hormone releasing hormone (GHRH). The "no DAC" form lacks the drug affinity complex modification, giving it a shorter active window in research models. It is most often referred to by researchers as Modified GRF (1-29) or Mod GRF.
How it works
In growth hormone axis research, CJC-1295 (no DAC) is studied as a GHRH receptor agonist that participates in the pulsatile signaling pathway between the hypothalamus and the anterior pituitary. Its mechanism is most often investigated alongside ghrelin receptor agonists such as Ipamorelin in synergy studies.
What researchers explore it for
Researchers have explored CJC-1295 (no DAC) in growth hormone pulsatility research, in combination pairing research with selective ghrelin receptor agonists, and in research on the GHRH receptor itself.
Safety and interactions
Research interactions of note include combinations with ghrelin receptor agonists, which are commonly investigated together and can compound observed effects in research models. CJC-1295 (no DAC) is for laboratory research use only and is not for human consumption. Not medical advice. Not intended to diagnose, treat, cure, or prevent any disease.
Research notes
Peptide family: GHRH analogs. Frequently compared with Sermorelin and CJC-1295 with DAC. Commonly researched alongside Ipamorelin, GHRP-2, GHRP-6, and Hexarelin. Lyophilized powder; reconstitution and storage handling per laboratory protocols.
Related peptides: Ipamorelin · GHRP-2 · GHRP-6 · Hexarelin